<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066974</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH102-REC2-112</org_study_id>
    <nct_id>NCT02066974</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy</brief_title>
  <official_title>Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients&#xD;
      were presented with advanced disease. Percutaneous ethanol injection, radiofrequency&#xD;
      ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a&#xD;
      curative treatment and have achieved very limited success in eradicating large HCC or tumors&#xD;
      causing portal vein thrombosis. With the development of novel radiotherapy (RT) technique, RT&#xD;
      can be safely given to patients with larger tumor or portal vein thrombosis. However, RT&#xD;
      could achieve a tumor response rate of approximately 50 %. Currently, there was a paucity of&#xD;
      studies regarding a quantitative biomarker to predict tumor response or forecast the outcome&#xD;
      in advance. To optimize the therapeutic index, there is a need to seek effective biomarkers&#xD;
      for personal medicine because pretreatment AFP is not always useful as a surrogate marker in&#xD;
      some of the patients.&#xD;
&#xD;
      The present study is to investigate whether circulating tumor cell genome in peripheral blood&#xD;
      can be used to predict RT response in HCC. We will use the blood sample from patients with&#xD;
      locally advanced HCC receiving RT. By using next generation sequencing, We are going to&#xD;
      explore the quantity and quality changes of DNAs and RNAs in the patient's serum or plasma.&#xD;
      By this way, genomic expression in peripheral blood may play a key role in determining the&#xD;
      optimal therapeutic strategies for HCC patients by predicting tumor response to RT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hepatocellular carcinoma requiring radiotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>one month</time_frame>
    <description>The correlation between response rate and circulating tumor cell genome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, relapse-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Circulating Neoplastic Cells</condition>
  <condition>Adverse Effect of Radiation Therapy</condition>
  <condition>Fatal Outcome</condition>
  <arm_group>
    <arm_group_label>Hepatoma, Circulating tumor genome</arm_group_label>
    <description>Hepatoma requiring radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>hepatoma requiring radiotherapy</intervention_name>
    <description>hepatoma requiring radiotherapy</description>
    <arm_group_label>Hepatoma, Circulating tumor genome</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fragmented DNA and RNA, Methylation&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with advanced hepatoma requiring radiotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with unresectable hepatoma with transarterial chemoembolization (TACE)&#xD;
             failure or who are not suitable for TACE. A maximal tumor diameter &gt; 3.0 cm&#xD;
&#xD;
          -  Age &gt; 20, and &lt; 80 years&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Child-Pugh A&#xD;
&#xD;
          -  Cancer of the Liver Italian Program (CLIP) score ≦ 3&#xD;
&#xD;
          -  Pretreatment liver function test and renal function test:Total bilirubin &lt; 1.5 times&#xD;
             the upper limit of normal (ULN), GOP/GPT ≦ 5 X of upper limit of normal range,&#xD;
             Alkaline phosphatase ≦ 4X of ULN, Prothrombin time / partial prothrombin time &lt; 1.5 X&#xD;
             of ULN, Serum Creatinine ≦ 1.0 x ULN&#xD;
&#xD;
          -  Pretreatment blood count:Hemoglobulin ≧ 9 g/dl, Absolute neutrophil count ≧&#xD;
             1500/mm3,Platelet count ≧ 100,000/mm3&#xD;
&#xD;
          -  Subjects with at least one uni-dimensional or bi-dimensional measurable lesion and&#xD;
             lesion must be measured by CT scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh C&#xD;
&#xD;
          -  CLIP score ≧ 4&#xD;
&#xD;
          -  Patients with evidence of extrahepatic or metastatic disease&#xD;
&#xD;
          -  Patients with evidence of massive ascites&#xD;
&#xD;
          -  Patients receiving previous irradiation to liver&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shang-Wen Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>China Medical University Hosptal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Shang-Wen Chen</investigator_full_name>
    <investigator_title>Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>genomic expression</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

